Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer

This post hoc analysis of a multi-institution cohort study assesses the association between androgen receptor perturbation and poorer outcome in patients with TP53 wild-type metastatic castration-resistant prostate cancer who are receiving abiraterone or enzalutamide.

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:JAMA Oncol
Prif Awduron: De Laere, Bram, Rajan, Prabhakar, Grönberg, Henrik, Dirix, Luc, Lindberg, Johan
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Medical Association 2019
Pynciau:
Research Letter
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6499126/
https://ncbi.nlm.nih.gov/pubmed/31046065
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.0869
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg